ASCO: Cilta-Cel Beneficial for Lenalidomide-Refractory Multiple Myeloma

THURSDAY, June 8, 2023 -- For patients with lenalidomide-refractory multiple myeloma, a single cilta-cel infusion results in lower risk of disease progression or death compared with standard care, according to a study published online June 5 in the...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news